- Home
- DXR
as of 10-30-2026 3:43pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 59.0M | IPO Year: | 1995 |
| Target Price: | $20.00 | AVG Volume (30 days): | 9.9K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $8.56 - $14.76 | Next Earning Date: | 11-13-2026 |
| Revenue: | $1,446,345 | Revenue Growth: | -8.42% |
| Revenue Growth (this year): | 44489.33% | Revenue Growth (next year): | 74.79% |
| P/E Ratio: | 33.83 | Index: | N/A |
| Free Cash Flow: | -6631798.0 | FCF Growth: | N/A |
Compare DXR vs Leading Stocks
See how DXR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.